PA5-27462

antibody from Invitrogen Antibodies

Targeting: ANXA6 ANX6

Western blot (Data presented on provider website)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-27462

Provider

Invitrogen Antibodies

Product name

Annexin A6 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Recommended positive controls: H1299, NIH-3T3. Predicted reactivity: Mouse (95%), Rat (95%), Chicken (80%), Bovine (96%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Reactivity

Human, Mouse

Host

Rabbit

Isotype

IgG

Vial size

100 μL

Concentration

0.179 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

iTRAQ-based quantitative proteomics reveals biomarkers/pathways in psoriasis that can predict the efficacy of methotrexate.

Yan KX, Meng Q, He H, Zhu HW, Wang ZC, Han L, Huang Q, Zhang ZH, Yawalkar N, Zhou H, Xu JX
Journal of the European Academy of Dermatology and Venereology : JEADV 2022 Oct;36(10):1784-1795

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Annexin A6 Polyclonal Antibody detects ANXA6 protein at cytosol on human breast by immunohistochemical analysis. Sample: Paraffin-embedded breast. Annexin A6 Polyclonal Antibody (Product # PA5-27462) dilution: 1:500.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

5 Figure Validation of STAT1 and ANXA6 proteins by Western blot. (a) The PASI score in nine GRs at baseline, 4 W, and 8 W. (b) Western blot analysis of expression levels of STAT1 and ANXA6 in GRs at baseline (0 W) and week 8 (8 W) after MTX treatment. (c) The expression of STAT1 and ANXA6 protein was significantly downregulated after MTX treatment (paired t -test, ** P < 0.01). (d) The PASI score in 9 NRs at baseline, 4 W and 8 W. (e) Western blot analysis of expression levels of STAT1 and ANXA6 in NRs at baseline (0 W) and week 8 (8 W) after MTX treatment. (f) The expression of STAT1 and ANXA6 protein in NR was not significantly downregulated after MTX treatment (paired t -test, P > 0.05). GR, good-responder; NR, non-responder; ns, no significance.